A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our decentralized manufacturing strategy and rapid release testing, enables delivery ...

A new avenue for targeted drug delivery has been proposed by researchers from The Grainger College of Engineering at the ...

Imagine cells navigating through a complex maze, guided by chemical signals and the physical landscape of their environment.

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce ...

Muscimol, a GABA-A (GABAA) receptor agonist, enhances GABA's inhibitory effect on neuronal activity by activating GABAA ...

The future is bright for prostate cancer research. It's glowing, in fact, thanks to new tools that combine the eye-catching fluorescence of microscopy with next-generation sequencing tools.

Compared with the traditional VSV-G pseudotyped lentiviral vector, MxV-G pseudotyped vector not only enhances viral titer and transduction efficiency but also enables generated CAR-T cells to more ...

Compared with the traditional VSV-G pseudotyped lentiviral vector, MxV-G pseudotyped vector not only enhances viral titer and transduction efficiency but also enables generated CAR-T cells to more ...

Immunofoco, a company dedicated to advancing cell therapies for solid tumors, announced that its independently developed, innovative lentiviral vector-based In Vivo CAR-T Technology Platform made a ...

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...